Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Enoxaparin
- Accession Number
- DB01225 (APRD00068)
- Type
- Small Molecule
- Groups
- Approved
- Description
Enoxaparin is a low molecular weight heparin. Enoxaparin is used to prevent and treat deep vein thrombosis or pulmonary embolism, and is given as a subcutaneous injection. Enoxaparin binds to and accelerates the activity of antithrombin III. By activating antithrombin III, enoxaparin preferentially potentiates the inhibition of coagulation factors Xa and IIa. Factor Xa catalyzes the conversion of prothrombin to thrombin, so enoxaparin's inhibition of this process results in decreased thrombin and ultimately the prevention of fibrin clot formation. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
- Synonyms
- Enoxaparin sodium
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Lovenox Injection 300 mg/3mL Intravenous; Subcutaneous Sanofi Aventis 1993-03-29 Not applicable US 
Lovenox Injection 40 mg/.4mL Intravenous; Subcutaneous Cardinal Health 1993-03-29 Not applicable US Lovenox Injection 80 mg/.8mL Intravenous; Subcutaneous Cardinal Health 1993-03-29 Not applicable US Lovenox Solution 100 mg Subcutaneous Sanofi Aventis 2012-09-21 Not applicable Canada 
Lovenox Injection 80 mg/.8mL Intravenous; Subcutaneous Sanofi Aventis 1993-03-29 Not applicable US Lovenox Injection 80 mg/.8mL Intravenous; Subcutaneous Physicians Total Care, Inc. 2004-07-28 Not applicable US Lovenox Injection 60 mg/.6mL Intravenous; Subcutaneous Sanofi Aventis 1993-03-29 Not applicable US Lovenox Injection 150 mg/mL Intravenous; Subcutaneous Sanofi Aventis 1993-03-29 Not applicable US Lovenox Injection 30 mg/.3mL Intravenous; Subcutaneous Cardinal Health 1993-03-29 Not applicable US Lovenox Injection 30 mg/.3mL Intravenous; Subcutaneous Sanofi Aventis 1993-03-29 Not applicable US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Enoxaparin Sodium Injection 100 mg/mL Intravenous; Subcutaneous Sandoz 2012-04-23 2017-11-30 US Enoxaparin Sodium Injection 100 mg/mL Subcutaneous Cardinal Health 2010-07-23 Not applicable US Enoxaparin Sodium Injection 100 mg/mL Subcutaneous Amphastar Pharmaceuticals, Inc. 2011-09-19 Not applicable US Enoxaparin sodium Injection 120 mg/.8mL Subcutaneous Winthrop U.S. 2011-10-03 Not applicable US Enoxaparin sodium Injection 30 mg/.3mL Subcutaneous Winthrop U.S. 2011-10-03 Not applicable US Enoxaparin Sodium Injection 100 mg/mL Subcutaneous Cardinal Health 2010-07-23 Not applicable US Enoxaparin Sodium Injection 120 mg/.8mL Subcutaneous Actavis Pharma Company 2012-01-27 2018-06-30 US Enoxaparin Sodium Injection 100 mg/mL Subcutaneous Amphastar Pharmaceuticals, Inc. 2011-09-19 Not applicable US Enoxaparin sodium Injection 100 mg/mL Subcutaneous Cardinal Health 2015-02-20 Not applicable US Enoxaparin Sodium Injection, solution 40 mg/.4mL Intravenous; Subcutaneous Teva Parenteral Medicines, Inc. 2014-09-26 Not applicable US - International/Other Brands
- Clexane
- Categories
- UNII
- 8NZ41MIK1O
- CAS number
- 9005-49-6
- Weight
- Not Available
- Chemical Formula
- Not Available
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
Pharmacology
- Indication
For the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, and also for the prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin.
- Structured Indications
- Pharmacodynamics
Enoxaparin is a highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from 3800 to 5000 daltons. Enoxaparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Enoxaparin is a well known and commonly used anticoagulant which has antithrombotic properties. Enoxaparin inhibits reactions that lead to the clotting of blood and the formation of fibrin clots both in vitro and in vivo. Enoxaparin acts at multiple sites in the normal coagulation system. Small amounts of enoxaparin in combination with antithrombin III (enoxaparin cofactor) can inhibit thrombosis by inactivating activated Factor X and inhibiting the conversion of prothrombin to thrombin. Once active thrombosis has developed, larger amounts of enoxaparin can inhibit further coagulation by inactivating thrombin and preventing the conversion of fibrinogen to fibrin. Enoxaparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor. Its use should be avoided in patients with a creatinine clearance less than 20mL/min. In these patients, unfractionated heparin should only be used. As for monitoring, active partial thromboplastin time (aPTT) will only increase at high doses of low molecular weight heparins (LMWH). Therefore, monitoring aPTT is not recommended. However, anti-Xa activity can be measured to monitor the efficacy of the LMWH.
- Mechanism of action
The mechanism of action of enoxaparin is antithrombin-dependent. It acts mainly by accelerating the rate of the neutralization of certain activated coagulation factors by antithrombin, but other mechanisms may also be involved. The antithrombotic effect of enoxaparin is well correlated to the inhibition of factor Xa. Enoxaparin interacts with Antithrombin III, Prothrombin and Factor X. Enoxaparin binds to and accelerates the activity of antithrombin III. By activating antithrombin III, enoxaparin preferentially potentiates the inhibition of coagulation factors Xa and IIa.
Target Actions Organism AAntithrombin-III potentiatorHuman ACoagulation factor X inhibitorHuman - Absorption
Mean absolute bioavailability of enoxaparin, after 1.5 mg/kg given subcutaneously, based on anti-Factor Xa activity is approximately 100% in healthy volunteers.
- Volume of distribution
- 4.3 L
- Protein binding
80% bound-albumin
- Metabolism
Undergoes desulfation and polymerization via the liver
- Route of elimination
Enoxaparin sodium is primarily metabolized in the liver by desulfation and/or depolymerization to lower molecular weight species with much reduced biological potency. Renal clearance of active fragments represents about 10% of the administered dose and total renal excretion of active and non-active fragments 40% of the dose.
- Half life
4.5 hours
- Clearance
- Not Available
- Toxicity
Mouse, median lethal dose greater than 5000 mg/kg. Another side effect is heparin induced thrombocytopenia (HIT syndrome). HIT is caused by an immunological reaction that makes platelets form clots within the blood vessels, thereby using up coagulation factors.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene (4R)-limonene may increase the anticoagulant activities of Enoxaparin. Investigational Abciximab Abciximab may increase the anticoagulant activities of Enoxaparin. Approved Aceclofenac Aceclofenac may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Acemetacin The risk or severity of bleeding can be increased when Enoxaparin is combined with Acemetacin. Approved, Experimental, Investigational Acenocoumarol Enoxaparin may increase the anticoagulant activities of Acenocoumarol. Approved, Investigational Acetylsalicylic acid Acetylsalicylic acid may increase the anticoagulant activities of Enoxaparin. Approved, Vet Approved Adapalene Adapalene may increase the anticoagulant activities of Enoxaparin. Approved Alclofenac Alclofenac may increase the anticoagulant activities of Enoxaparin. Approved, Withdrawn Aliskiren Enoxaparin may increase the hyperkalemic activities of Aliskiren. Approved, Investigational Allylestrenol The therapeutic efficacy of Enoxaparin can be decreased when used in combination with Allylestrenol. Approved Alminoprofen Alminoprofen may increase the anticoagulant activities of Enoxaparin. Experimental Aloxiprin Aloxiprin may increase the anticoagulant activities of Enoxaparin. Experimental Alprostadil Alprostadil may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Alteplase Alteplase may increase the anticoagulant activities of Enoxaparin. Approved Altrenogest The therapeutic efficacy of Enoxaparin can be decreased when used in combination with Altrenogest. Vet Approved Amiloride Enoxaparin may increase the hyperkalemic activities of Amiloride. Approved Aminosalicylic Acid Aminosalicylic Acid may increase the anticoagulant activities of Enoxaparin. Approved Anagrelide Anagrelide may increase the anticoagulant activities of Enoxaparin. Approved Ancrod Enoxaparin may increase the anticoagulant activities of Ancrod. Approved, Investigational Andrographolide Andrographolide may increase the anticoagulant activities of Enoxaparin. Investigational Anisodamine Anisodamine may increase the anticoagulant activities of Enoxaparin. Investigational Anistreplase Anistreplase may increase the anticoagulant activities of Enoxaparin. Approved Antipyrine Antipyrine may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Antithrombin III human Enoxaparin may increase the anticoagulant activities of Antithrombin III human. Approved Apixaban Apixaban may increase the anticoagulant activities of Enoxaparin. Approved Apocynin Apocynin may increase the anticoagulant activities of Enoxaparin. Investigational Apremilast Apremilast may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Aprotinin The therapeutic efficacy of Enoxaparin can be decreased when used in combination with Aprotinin. Approved, Investigational, Withdrawn Ardeparin Ardeparin may increase the anticoagulant activities of Enoxaparin. Approved, Investigational, Withdrawn Argatroban Argatroban may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Astaxanthin Astaxanthin may increase the anticoagulant activities of Enoxaparin. Investigational Azapropazone Azapropazone may increase the anticoagulant activities of Enoxaparin. Withdrawn Azelastine Azelastine may increase the anticoagulant activities of Enoxaparin. Approved Azficel-T The risk or severity of adverse effects can be increased when Enoxaparin is combined with Azficel-T. Approved, Investigational Azilsartan medoxomil Enoxaparin may increase the hyperkalemic activities of Azilsartan medoxomil. Approved, Investigational Balsalazide Balsalazide may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Batroxobin Batroxobin may increase the anticoagulant activities of Enoxaparin. Experimental Becaplermin Becaplermin may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Bemiparin Bemiparin may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Bendazac Bendazac may increase the anticoagulant activities of Enoxaparin. Experimental Benorilate Benorilate may increase the anticoagulant activities of Enoxaparin. Experimental Benoxaprofen Benoxaprofen may increase the anticoagulant activities of Enoxaparin. Withdrawn Benzydamine Benzydamine may increase the anticoagulant activities of Enoxaparin. Approved Beraprost Beraprost may increase the anticoagulant activities of Enoxaparin. Investigational Bevonium Bevonium may increase the anticoagulant activities of Enoxaparin. Experimental Bivalirudin Bivalirudin may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Brinase Brinase may increase the anticoagulant activities of Enoxaparin. Experimental Bromfenac Bromfenac may increase the anticoagulant activities of Enoxaparin. Approved Bucillamine Bucillamine may increase the anticoagulant activities of Enoxaparin. Investigational Bufexamac Bufexamac may increase the anticoagulant activities of Enoxaparin. Approved, Experimental Buflomedil Buflomedil may increase the anticoagulant activities of Enoxaparin. Experimental Bumadizone Bumadizone may increase the anticoagulant activities of Enoxaparin. Experimental Butylphthalide Butylphthalide may increase the anticoagulant activities of Enoxaparin. Investigational Canagliflozin Enoxaparin may increase the hyperkalemic activities of Canagliflozin. Approved Candesartan Enoxaparin may increase the hyperkalemic activities of Candesartan. Experimental Candesartan cilexetil Enoxaparin may increase the hyperkalemic activities of Candesartan cilexetil. Approved Cangrelor Cangrelor may increase the anticoagulant activities of Enoxaparin. Approved Caplacizumab Caplacizumab may increase the anticoagulant activities of Enoxaparin. Investigational Carbaspirin calcium Carbaspirin calcium may increase the anticoagulant activities of Enoxaparin. Experimental, Investigational Carprofen Carprofen may increase the anticoagulant activities of Enoxaparin. Approved, Vet Approved, Withdrawn Castanospermine Castanospermine may increase the anticoagulant activities of Enoxaparin. Experimental Celecoxib Celecoxib may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Certoparin Enoxaparin may increase the anticoagulant activities of Certoparin. Approved, Investigational Chloroquine Chloroquine may increase the anticoagulant activities of Enoxaparin. Approved, Investigational, Vet Approved Chlorotrianisene Chlorotrianisene may decrease the anticoagulant activities of Enoxaparin. Investigational, Withdrawn Choline magnesium trisalicylate Choline magnesium trisalicylate may increase the anticoagulant activities of Enoxaparin. Approved Cilostazol Cilostazol may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Citric Acid Enoxaparin may increase the anticoagulant activities of Citric Acid. Approved, Nutraceutical, Vet Approved Clonixin Clonixin may increase the anticoagulant activities of Enoxaparin. Approved Clopidogrel Clopidogrel may increase the anticoagulant activities of Enoxaparin. Approved Cloricromen Cloricromen may increase the anticoagulant activities of Enoxaparin. Experimental Clorindione Clorindione may increase the anticoagulant activities of Enoxaparin. Experimental Collagenase clostridium histolyticum The risk or severity of adverse effects can be increased when Enoxaparin is combined with Collagenase clostridium histolyticum. Approved, Investigational Conjugated estrogens Conjugated estrogens may decrease the anticoagulant activities of Enoxaparin. Approved Curcumin Curcumin may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Dabigatran etexilate Dabigatran etexilate may increase the anticoagulant activities of Enoxaparin. Approved Daidzein Daidzein may decrease the anticoagulant activities of Enoxaparin. Experimental Dalteparin Enoxaparin may increase the anticoagulant activities of Dalteparin. Approved Danaparoid Enoxaparin may increase the anticoagulant activities of Danaparoid. Approved, Withdrawn Darexaban Enoxaparin may increase the anticoagulant activities of Darexaban. Investigational Dasatinib Dasatinib may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Deferasirox The risk or severity of adverse effects can be increased when Enoxaparin is combined with Deferasirox. Approved, Investigational Defibrotide Defibrotide may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Demegestone The therapeutic efficacy of Enoxaparin can be decreased when used in combination with Demegestone. Experimental Deoxycholic Acid The risk or severity of adverse effects can be increased when Enoxaparin is combined with Deoxycholic Acid. Approved Dersalazine Dersalazine may increase the anticoagulant activities of Enoxaparin. Investigational Desirudin Enoxaparin may increase the anticoagulant activities of Desirudin. Approved Desmoteplase Desmoteplase may increase the anticoagulant activities of Enoxaparin. Investigational Desogestrel The therapeutic efficacy of Enoxaparin can be decreased when used in combination with Desogestrel. Approved Dextran Enoxaparin may increase the anticoagulant activities of Dextran. Approved, Investigational, Vet Approved Dextran 40 Enoxaparin may increase the anticoagulant activities of Dextran 40. Approved Dextran 70 Enoxaparin may increase the anticoagulant activities of Dextran 70. Approved Dextran 75 Enoxaparin may increase the anticoagulant activities of Dextran 75. Approved Diclofenac Diclofenac may increase the anticoagulant activities of Enoxaparin. Approved, Vet Approved Dicoumarol Dicoumarol may increase the anticoagulant activities of Enoxaparin. Approved Dienestrol Dienestrol may decrease the anticoagulant activities of Enoxaparin. Approved, Investigational Dienogest The therapeutic efficacy of Enoxaparin can be decreased when used in combination with Dienogest. Approved Diethylstilbestrol Diethylstilbestrol may decrease the anticoagulant activities of Enoxaparin. Approved, Investigational Difenpiramide Difenpiramide may increase the anticoagulant activities of Enoxaparin. Experimental Diflunisal Diflunisal may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Diphenadione Diphenadione may increase the anticoagulant activities of Enoxaparin. Experimental Dipyridamole Dipyridamole may increase the anticoagulant activities of Enoxaparin. Approved Ditazole Ditazole may increase the anticoagulant activities of Enoxaparin. Approved, Withdrawn Drotrecogin alfa Drotrecogin alfa may increase the anticoagulant activities of Enoxaparin. Approved, Investigational, Withdrawn Droxicam Droxicam may increase the anticoagulant activities of Enoxaparin. Withdrawn Duvelisib Duvelisib may increase the anticoagulant activities of Enoxaparin. Investigational Dydrogesterone The therapeutic efficacy of Enoxaparin can be decreased when used in combination with Dydrogesterone. Approved, Investigational, Withdrawn E-6201 E-6201 may increase the anticoagulant activities of Enoxaparin. Investigational Edetic Acid Edetic Acid may increase the anticoagulant activities of Enoxaparin. Approved, Vet Approved Edoxaban Edoxaban may increase the anticoagulant activities of Enoxaparin. Approved Epimestrol Epimestrol may decrease the anticoagulant activities of Enoxaparin. Experimental Epinastine Epinastine may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Epirizole Epirizole may increase the anticoagulant activities of Enoxaparin. Approved Eplerenone Enoxaparin may increase the hyperkalemic activities of Eplerenone. Approved Eplivanserin Eplivanserin may increase the anticoagulant activities of Enoxaparin. Investigational eplivanserine eplivanserine may increase the anticoagulant activities of Enoxaparin. Investigational Epoprostenol Epoprostenol may increase the anticoagulant activities of Enoxaparin. Approved Eprosartan Enoxaparin may increase the hyperkalemic activities of Eprosartan. Approved Eptifibatide Eptifibatide may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Equol Equol may decrease the anticoagulant activities of Enoxaparin. Investigational Estradiol Estradiol may decrease the anticoagulant activities of Enoxaparin. Approved, Investigational, Vet Approved Estradiol acetate Estradiol acetate may decrease the anticoagulant activities of Enoxaparin. Approved, Investigational, Vet Approved Estradiol cypionate Estradiol cypionate may decrease the anticoagulant activities of Enoxaparin. Approved, Investigational, Vet Approved Estradiol valerate Estradiol valerate may decrease the anticoagulant activities of Enoxaparin. Approved, Investigational, Vet Approved Estriol Estriol may decrease the anticoagulant activities of Enoxaparin. Approved, Investigational, Vet Approved Estrogens, esterified Estrogens, esterified may decrease the anticoagulant activities of Enoxaparin. Approved Estrone Estrone may decrease the anticoagulant activities of Enoxaparin. Approved Etanercept Etanercept may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Ethenzamide Ethenzamide may increase the anticoagulant activities of Enoxaparin. Experimental Ethinyl Estradiol Ethinyl Estradiol may decrease the anticoagulant activities of Enoxaparin. Approved Ethyl biscoumacetate Enoxaparin may increase the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Etodolac Etodolac may increase the anticoagulant activities of Enoxaparin. Approved, Investigational, Vet Approved Etofenamate Etofenamate may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Etonogestrel The therapeutic efficacy of Enoxaparin can be decreased when used in combination with Etonogestrel. Approved, Investigational Etoricoxib Etoricoxib may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Evening primrose oil Evening primrose oil may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Exisulind Exisulind may increase the anticoagulant activities of Enoxaparin. Investigational Felbinac Felbinac may increase the anticoagulant activities of Enoxaparin. Experimental Fenbufen Fenbufen may increase the anticoagulant activities of Enoxaparin. Approved Fenoprofen Fenoprofen may increase the anticoagulant activities of Enoxaparin. Approved Fentiazac Fentiazac may increase the anticoagulant activities of Enoxaparin. Experimental Feprazone Feprazone may increase the anticoagulant activities of Enoxaparin. Experimental Ferulic acid Ferulic acid may increase the anticoagulant activities of Enoxaparin. Experimental Fibrinolysin Fibrinolysin may increase the anticoagulant activities of Enoxaparin. Investigational Fimasartan Enoxaparin may increase the hyperkalemic activities of Fimasartan. Approved, Investigational Floctafenine Floctafenine may increase the anticoagulant activities of Enoxaparin. Approved, Withdrawn Fluindione Enoxaparin may increase the anticoagulant activities of Fluindione. Approved, Investigational Flunixin Flunixin may increase the anticoagulant activities of Enoxaparin. Vet Approved Flunoxaprofen Flunoxaprofen may increase the anticoagulant activities of Enoxaparin. Experimental Flurbiprofen Flurbiprofen may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Fondaparinux Enoxaparin may increase the anticoagulant activities of Fondaparinux. Approved, Investigational Fondaparinux sodium Fondaparinux sodium may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Forasartan Enoxaparin may increase the hyperkalemic activities of Forasartan. Experimental Gabexate Enoxaparin may increase the anticoagulant activities of Gabexate. Investigational Genistein Genistein may decrease the anticoagulant activities of Enoxaparin. Investigational Gestodene The therapeutic efficacy of Enoxaparin can be decreased when used in combination with Gestodene. Approved, Investigational Gestonorone The therapeutic efficacy of Enoxaparin can be decreased when used in combination with Gestonorone. Experimental Gestrinone The therapeutic efficacy of Enoxaparin can be decreased when used in combination with Gestrinone. Approved Guacetisal Guacetisal may increase the anticoagulant activities of Enoxaparin. Experimental Hemin Hemin may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Hemoglobin crosfumaril Hemoglobin crosfumaril may increase the anticoagulant activities of Enoxaparin. Experimental Heparin Heparin may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Hexestrol Hexestrol may decrease the anticoagulant activities of Enoxaparin. Withdrawn Higenamine Higenamine may increase the anticoagulant activities of Enoxaparin. Investigational Hydroxyprogesterone caproate The therapeutic efficacy of Enoxaparin can be decreased when used in combination with Hydroxyprogesterone caproate. Approved, Investigational Hydroxytyrosol Hydroxytyrosol may increase the anticoagulant activities of Enoxaparin. Investigational Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Enoxaparin is combined with Ibritumomab tiuxetan. Approved, Investigational Ibrutinib The risk or severity of adverse effects can be increased when Ibrutinib is combined with Enoxaparin. Approved Ibudilast Ibudilast may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Ibuprofen Ibuprofen may increase the anticoagulant activities of Enoxaparin. Approved Ibuproxam Ibuproxam may increase the anticoagulant activities of Enoxaparin. Withdrawn Icatibant Icatibant may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Icosapent ethyl Icosapent ethyl may increase the anticoagulant activities of Enoxaparin. Approved, Investigational, Nutraceutical Idraparinux Enoxaparin may increase the anticoagulant activities of Idraparinux. Investigational Ifenprodil Ifenprodil may increase the anticoagulant activities of Enoxaparin. Approved, Investigational, Withdrawn Ifetroban Ifetroban may increase the anticoagulant activities of Enoxaparin. Investigational Iloprost Iloprost may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Imidazole salicylate Imidazole salicylate may increase the anticoagulant activities of Enoxaparin. Experimental Indobufen Indobufen may increase the anticoagulant activities of Enoxaparin. Investigational Indomethacin Indomethacin may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Indoprofen Indoprofen may increase the anticoagulant activities of Enoxaparin. Withdrawn Irbesartan Enoxaparin may increase the hyperkalemic activities of Irbesartan. Approved, Investigational Isoxicam Isoxicam may increase the anticoagulant activities of Enoxaparin. Withdrawn Kebuzone Kebuzone may increase the anticoagulant activities of Enoxaparin. Experimental Ketanserin Ketanserin may increase the anticoagulant activities of Enoxaparin. Investigational Ketoprofen Ketoprofen may increase the anticoagulant activities of Enoxaparin. Approved, Vet Approved Ketorolac Ketorolac may increase the anticoagulant activities of Enoxaparin. Approved Leflunomide Leflunomide may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Lepirudin Lepirudin may increase the anticoagulant activities of Enoxaparin. Approved Letaxaban Enoxaparin may increase the anticoagulant activities of Letaxaban. Investigational Levonorgestrel The therapeutic efficacy of Enoxaparin can be decreased when used in combination with Levonorgestrel. Approved, Investigational Limaprost The risk or severity of adverse effects can be increased when Limaprost is combined with Enoxaparin. Approved, Investigational Linsidomine Linsidomine may increase the anticoagulant activities of Enoxaparin. Experimental Lisofylline Lisofylline may increase the anticoagulant activities of Enoxaparin. Investigational Lonazolac Lonazolac may increase the anticoagulant activities of Enoxaparin. Experimental Lornoxicam Lornoxicam may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Losartan Enoxaparin may increase the hyperkalemic activities of Losartan. Approved Loxoprofen Loxoprofen may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Lumiracoxib Lumiracoxib may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Magnesium salicylate Magnesium salicylate may increase the anticoagulant activities of Enoxaparin. Approved Masoprocol Masoprocol may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Meclofenamic acid Meclofenamic acid may increase the anticoagulant activities of Enoxaparin. Approved, Vet Approved Medrogestone The therapeutic efficacy of Enoxaparin can be decreased when used in combination with Medrogestone. Approved Medroxyprogesterone acetate The therapeutic efficacy of Enoxaparin can be decreased when used in combination with Medroxyprogesterone acetate. Approved, Investigational Mefenamic acid Mefenamic acid may increase the anticoagulant activities of Enoxaparin. Approved Megestrol acetate The therapeutic efficacy of Enoxaparin can be decreased when used in combination with Megestrol acetate. Approved, Investigational, Vet Approved Melagatran Enoxaparin may increase the anticoagulant activities of Melagatran. Experimental Meloxicam Meloxicam may increase the anticoagulant activities of Enoxaparin. Approved, Vet Approved Mesalazine Mesalazine may increase the anticoagulant activities of Enoxaparin. Approved Mestranol Mestranol may decrease the anticoagulant activities of Enoxaparin. Approved Metamizole Metamizole may increase the anticoagulant activities of Enoxaparin. Approved, Investigational, Withdrawn Methallenestril Methallenestril may decrease the anticoagulant activities of Enoxaparin. Experimental Methyl salicylate Methyl salicylate may increase the anticoagulant activities of Enoxaparin. Approved, Vet Approved Methylestrenolone The therapeutic efficacy of Enoxaparin can be decreased when used in combination with Methylestrenolone. Experimental Milrinone Milrinone may increase the anticoagulant activities of Enoxaparin. Approved Mizoribine Mizoribine may increase the anticoagulant activities of Enoxaparin. Investigational Mofebutazone Mofebutazone may increase the anticoagulant activities of Enoxaparin. Experimental Moxestrol Moxestrol may decrease the anticoagulant activities of Enoxaparin. Experimental Mycophenolate mofetil Mycophenolate mofetil may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Mycophenolic acid Mycophenolic acid may increase the anticoagulant activities of Enoxaparin. Approved Nabumetone Nabumetone may increase the anticoagulant activities of Enoxaparin. Approved Nadroparin Enoxaparin may increase the anticoagulant activities of Nadroparin. Approved, Investigational Nafamostat Nafamostat may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Naftifine Naftifine may increase the anticoagulant activities of Enoxaparin. Approved Naftopidil Naftopidil may increase the anticoagulant activities of Enoxaparin. Investigational Naproxen Naproxen may increase the anticoagulant activities of Enoxaparin. Approved, Vet Approved Nepafenac Nepafenac may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Nifenazone Nifenazone may increase the anticoagulant activities of Enoxaparin. Experimental Niflumic Acid Niflumic Acid may increase the anticoagulant activities of Enoxaparin. Approved Nimesulide Nimesulide may increase the anticoagulant activities of Enoxaparin. Approved, Investigational, Withdrawn Nintedanib The risk or severity of adverse effects can be increased when Enoxaparin is combined with Nintedanib. Approved Nitroaspirin Nitroaspirin may increase the anticoagulant activities of Enoxaparin. Investigational Nomegestrol The therapeutic efficacy of Enoxaparin can be decreased when used in combination with Nomegestrol. Approved Norethisterone The therapeutic efficacy of Enoxaparin can be decreased when used in combination with Norethisterone. Approved Norgestrienone The therapeutic efficacy of Enoxaparin can be decreased when used in combination with Norgestrienone. Experimental Obinutuzumab The risk or severity of adverse effects can be increased when Enoxaparin is combined with Obinutuzumab. Approved, Investigational Olmesartan Enoxaparin may increase the hyperkalemic activities of Olmesartan. Approved, Investigational Olopatadine Olopatadine may increase the anticoagulant activities of Enoxaparin. Approved Olsalazine Olsalazine may increase the anticoagulant activities of Enoxaparin. Approved Omacetaxine mepesuccinate The risk or severity of bleeding can be increased when Enoxaparin is combined with Omacetaxine mepesuccinate. Approved, Investigational Omega-3 fatty acids Omega-3 fatty acids may increase the anticoagulant activities of Enoxaparin. Approved, Nutraceutical Orgotein Orgotein may increase the anticoagulant activities of Enoxaparin. Vet Approved Otamixaban Enoxaparin may increase the anticoagulant activities of Otamixaban. Investigational Oxaprozin Oxaprozin may increase the anticoagulant activities of Enoxaparin. Approved Oxyphenbutazone Oxyphenbutazone may increase the anticoagulant activities of Enoxaparin. Approved, Withdrawn Ozagrel Ozagrel may increase the anticoagulant activities of Enoxaparin. Investigational Palifermin The serum concentration of Palifermin can be increased when it is combined with Enoxaparin. Approved Parecoxib Parecoxib may increase the anticoagulant activities of Enoxaparin. Approved Parnaparin Parnaparin may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Parthenolide Parthenolide may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Pentaerythritol Tetranitrate Enoxaparin may increase the anticoagulant activities of Pentaerythritol Tetranitrate. Approved Pentosan Polysulfate Pentosan Polysulfate may increase the anticoagulant activities of Enoxaparin. Approved Pentoxifylline Pentoxifylline may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Phenindione Phenindione may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Phenprocoumon Phenprocoumon may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Phenyl aminosalicylate Phenyl aminosalicylate may increase the anticoagulant activities of Enoxaparin. Approved Phenylbutazone Phenylbutazone may increase the anticoagulant activities of Enoxaparin. Approved, Vet Approved Picotamide Picotamide may increase the anticoagulant activities of Enoxaparin. Experimental Pimecrolimus Pimecrolimus may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Pirfenidone Pirfenidone may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Piroxicam Piroxicam may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Pirprofen Pirprofen may increase the anticoagulant activities of Enoxaparin. Experimental Polyestradiol phosphate Polyestradiol phosphate may decrease the anticoagulant activities of Enoxaparin. Approved Pranoprofen Pranoprofen may increase the anticoagulant activities of Enoxaparin. Experimental, Investigational Prasugrel Prasugrel may increase the anticoagulant activities of Enoxaparin. Approved Progesterone The therapeutic efficacy of Enoxaparin can be decreased when used in combination with Progesterone. Approved, Vet Approved Proglumetacin Proglumetacin may increase the anticoagulant activities of Enoxaparin. Experimental Promegestone The therapeutic efficacy of Enoxaparin can be decreased when used in combination with Promegestone. Experimental Promestriene Promestriene may decrease the anticoagulant activities of Enoxaparin. Investigational Propacetamol Propacetamol may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Propyphenazone Propyphenazone may increase the anticoagulant activities of Enoxaparin. Experimental Proquazone Proquazone may increase the anticoagulant activities of Enoxaparin. Experimental Protein C Enoxaparin may increase the anticoagulant activities of Protein C. Approved Protein S human Enoxaparin may increase the anticoagulant activities of Protein S human. Approved Protocatechualdehyde Enoxaparin may increase the anticoagulant activities of Protocatechualdehyde. Approved PTC299 PTC299 may increase the anticoagulant activities of Enoxaparin. Investigational Quinestrol Quinestrol may decrease the anticoagulant activities of Enoxaparin. Approved Ramatroban Ramatroban may increase the anticoagulant activities of Enoxaparin. Investigational Relcovaptan Relcovaptan may increase the anticoagulant activities of Enoxaparin. Investigational Resveratrol Resveratrol may increase the anticoagulant activities of Enoxaparin. Approved, Experimental, Investigational Reteplase Reteplase may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Reviparin Enoxaparin may increase the anticoagulant activities of Reviparin. Approved, Investigational Ridogrel Ridogrel may increase the anticoagulant activities of Enoxaparin. Approved Rivaroxaban Enoxaparin may increase the anticoagulant activities of Rivaroxaban. Approved Rofecoxib Rofecoxib may increase the anticoagulant activities of Enoxaparin. Approved, Investigational, Withdrawn Rosiglitazone Rosiglitazone may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Sacubitril Enoxaparin may increase the hyperkalemic activities of Sacubitril. Approved Salicylamide Salicylamide may increase the anticoagulant activities of Enoxaparin. Approved Salicylic acid Salicylic acid may increase the anticoagulant activities of Enoxaparin. Approved, Investigational, Vet Approved Salsalate Salsalate may increase the anticoagulant activities of Enoxaparin. Approved Saprisartan Enoxaparin may increase the hyperkalemic activities of Saprisartan. Experimental Saralasin Enoxaparin may increase the hyperkalemic activities of Saralasin. Investigational Sarpogrelate Sarpogrelate may increase the anticoagulant activities of Enoxaparin. Investigational Saruplase Saruplase may increase the anticoagulant activities of Enoxaparin. Experimental Secoisolariciresinol Secoisolariciresinol may decrease the anticoagulant activities of Enoxaparin. Investigational Selexipag Selexipag may increase the anticoagulant activities of Enoxaparin. Approved Semapimod Semapimod may increase the anticoagulant activities of Enoxaparin. Investigational Seratrodast Seratrodast may increase the anticoagulant activities of Enoxaparin. Approved Serrapeptase Serrapeptase may increase the anticoagulant activities of Enoxaparin. Investigational Sevoflurane Sevoflurane may increase the anticoagulant activities of Enoxaparin. Approved, Vet Approved Spironolactone Enoxaparin may increase the hyperkalemic activities of Spironolactone. Approved SRT501 SRT501 may increase the anticoagulant activities of Enoxaparin. Investigational Streptokinase Streptokinase may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Sugammadex Sugammadex may increase the anticoagulant activities of Enoxaparin. Approved Sulfasalazine Sulfasalazine may increase the anticoagulant activities of Enoxaparin. Approved Sulindac Sulindac may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Sulodexide Enoxaparin may increase the anticoagulant activities of Sulodexide. Approved, Investigational Suprofen Suprofen may increase the anticoagulant activities of Enoxaparin. Approved, Withdrawn Suxibuzone Suxibuzone may increase the anticoagulant activities of Enoxaparin. Experimental Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Enoxaparin. Approved Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Enoxaparin. Approved Tarenflurbil Tarenflurbil may increase the anticoagulant activities of Enoxaparin. Investigational Tasosartan Enoxaparin may increase the hyperkalemic activities of Tasosartan. Approved Telmisartan Enoxaparin may increase the hyperkalemic activities of Telmisartan. Approved, Investigational Tenecteplase Tenecteplase may increase the anticoagulant activities of Enoxaparin. Approved Tenidap Tenidap may increase the anticoagulant activities of Enoxaparin. Experimental Tenoxicam Tenoxicam may increase the anticoagulant activities of Enoxaparin. Approved Tepoxalin Tepoxalin may increase the anticoagulant activities of Enoxaparin. Vet Approved Teriflunomide Teriflunomide may increase the anticoagulant activities of Enoxaparin. Approved Tesmilifene Tesmilifene may increase the anticoagulant activities of Enoxaparin. Investigational Testosterone cypionate The therapeutic efficacy of Enoxaparin can be increased when used in combination with Testosterone cypionate. Approved Testosterone enanthate The therapeutic efficacy of Enoxaparin can be increased when used in combination with Testosterone enanthate. Approved Testosterone undecanoate The therapeutic efficacy of Enoxaparin can be increased when used in combination with Testosterone undecanoate. Approved, Investigational Tiaprofenic acid Tiaprofenic acid may increase the anticoagulant activities of Enoxaparin. Approved Tibolone Tibolone may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Ticagrelor Ticagrelor may increase the anticoagulant activities of Enoxaparin. Approved Ticlopidine Ticlopidine may increase the anticoagulant activities of Enoxaparin. Approved Tinoridine Tinoridine may increase the anticoagulant activities of Enoxaparin. Investigational Tinzaparin Tinzaparin may increase the anticoagulant activities of Enoxaparin. Approved Tioclomarol Tioclomarol may increase the anticoagulant activities of Enoxaparin. Experimental Tipranavir Tipranavir may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Tirofiban Tirofiban may increase the anticoagulant activities of Enoxaparin. Approved Tolfenamic Acid Tolfenamic Acid may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Tolmetin Tolmetin may increase the anticoagulant activities of Enoxaparin. Approved Tositumomab The risk or severity of adverse effects can be increased when Enoxaparin is combined with Tositumomab. Approved, Investigational Tranilast Tranilast may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Trapidil Trapidil may increase the anticoagulant activities of Enoxaparin. Approved Treprostinil Treprostinil may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Triamterene Enoxaparin may increase the hyperkalemic activities of Triamterene. Approved Tribenoside Tribenoside may increase the anticoagulant activities of Enoxaparin. Experimental Triflusal Triflusal may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Triptolide Triptolide may increase the anticoagulant activities of Enoxaparin. Investigational Trolamine salicylate Trolamine salicylate may increase the anticoagulant activities of Enoxaparin. Approved Troxerutin Enoxaparin may increase the anticoagulant activities of Troxerutin. Investigational Urokinase Urokinase may increase the anticoagulant activities of Enoxaparin. Approved, Investigational, Withdrawn Valdecoxib Valdecoxib may increase the anticoagulant activities of Enoxaparin. Approved, Investigational, Withdrawn Valsartan Enoxaparin may increase the hyperkalemic activities of Valsartan. Approved, Investigational Vitamin E Vitamin E may increase the anticoagulant activities of Enoxaparin. Approved, Nutraceutical, Vet Approved Vorapaxar The risk or severity of adverse effects can be increased when Vorapaxar is combined with Enoxaparin. Approved Warfarin Warfarin may increase the anticoagulant activities of Enoxaparin. Approved Ximelagatran Enoxaparin may increase the anticoagulant activities of Ximelagatran. Approved, Investigational, Withdrawn Zaltoprofen Zaltoprofen may increase the anticoagulant activities of Enoxaparin. Approved, Investigational Zeranol Zeranol may decrease the anticoagulant activities of Enoxaparin. Vet Approved Zileuton Zileuton may increase the anticoagulant activities of Enoxaparin. Approved, Investigational, Withdrawn Zomepirac Zomepirac may increase the anticoagulant activities of Enoxaparin. Withdrawn - Food Interactions
- Avoid danshen, dong quai, evening primrose oil, gingko, policosanol, willow bark
References
- Synthesis Reference
Jorgen I. Nielsen, "Process of using light absorption to control enzymatic depolymerization of heparin to produce low molecular weight heparin." U.S. Patent US5106734, issued May, 1981.
US5106734- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB14551
- KEGG Drug
- D07510
- PubChem Substance
- 46507450
- ChemSpider
- 751
- ChEMBL
- CHEMBL1201685
- Therapeutic Targets Database
- DAP000616
- PharmGKB
- PA449463
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Enoxaparin_sodium
- ATC Codes
- B01AB05 — Enoxaparin
- AHFS Codes
- 20:12.04.16 — Heparins
- FDA label
- Download (1.44 MB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Cardinal Health
- Lake Erie Medical and Surgical Supply
- Neuman Distributors Inc.
- Physicians Total Care Inc.
- Sanofi-Aventis Inc.
- Dosage forms
Form Route Strength Injection Subcutaneous 100 mg/mL Injection Subcutaneous 120 mg/.8mL Injection Subcutaneous 150 mg/mL Injection Subcutaneous 30 mg/.3mL Injection Subcutaneous 300 mg/3mL Injection Subcutaneous 40 mg/.4mL Injection Subcutaneous 60 mg/.6mL Injection Subcutaneous 80 mg/.8mL Injection, solution Intravenous; Subcutaneous 100 mg/mL Injection, solution Intravenous; Subcutaneous 120 mg/.8mL Injection, solution Intravenous; Subcutaneous 150 mg/mL Injection, solution Intravenous; Subcutaneous 30 mg/.3mL Injection, solution Intravenous; Subcutaneous 40 mg/.4mL Injection, solution Intravenous; Subcutaneous 60 mg/.6mL Injection, solution Intravenous; Subcutaneous 80 mg/.8mL Injection Intravenous; Subcutaneous 100 mg/mL Injection Intravenous; Subcutaneous 120 mg/.8mL Injection Intravenous; Subcutaneous 150 mg/mL Injection Intravenous; Subcutaneous 30 mg/.3mL Injection Intravenous; Subcutaneous 300 mg/3mL Injection Intravenous; Subcutaneous 40 mg/.4mL Injection Intravenous; Subcutaneous 60 mg/.6mL Injection Intravenous; Subcutaneous 80 mg/.8mL Solution Subcutaneous 100 mg Solution Subcutaneous 30 mg Solution Subcutaneous 40 mg Solution Subcutaneous 60 mg Solution Subcutaneous 80 mg Solution Subcutaneous 120 mg Solution Subcutaneous 150 mg Solution Subcutaneous 90 mg Solution Intravenous; Subcutaneous 100 mg - Prices
Unit description Cost Unit Lovenox 300 mg/3ml Solution 3ml Vial 281.47USD vial Lovenox 150 mg/ml Solution 1ml Syringe 140.94USD syringe Lovenox 100 mg/ml Solution 1ml Syringe 93.93USD syringe Lovenox 80 mg/0.8ml Solution 0.8ml Syringe 75.14USD syringe Lovenox 60 mg/0.6ml Solution 0.6ml Syringe 56.36USD syringe Lovenox 40 mg/0.4ml Solution 0.4ml Syringe 37.53USD syringe Lovenox Hp (0.8Ml/1Ml Syringe) 150 mg/ml Syringe 34.63USD syringe Lovenox 30 mg/0.3ml Solution 0.3ml Syringe 28.15USD syringe Lovenox (0.4 - 1 Ml Syringe) 100 mg/ml Syringe 23.09USD syringe Lovenox 100 mg/ml 23.09USD syringe Lovenox (0.3 Ml Syringe) 30 mg/syr Syringe 6.97USD syringe DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US5389618 No 1995-02-14 2012-02-14 US CA2045433 No 2002-07-30 2011-06-25 Canada
Properties
- State
- Solid
- Experimental Properties
Property Value Source water solubility > 200 mg/mL Not Available logP -13.2 Not Available - Predicted Properties
- Not Available
- Predicted ADMET features
Property Value Probability Human Intestinal Absorption - 0.9215 Blood Brain Barrier - 0.8366 Caco-2 permeable - 0.6496 P-glycoprotein substrate Non-substrate 0.698 P-glycoprotein inhibitor I Non-inhibitor 0.5818 P-glycoprotein inhibitor II Non-inhibitor 0.9771 Renal organic cation transporter Non-inhibitor 0.9454 CYP450 2C9 substrate Non-substrate 0.6694 CYP450 2D6 substrate Non-substrate 0.8196 CYP450 3A4 substrate Non-substrate 0.5842 CYP450 1A2 substrate Non-inhibitor 0.8157 CYP450 2C9 inhibitor Non-inhibitor 0.771 CYP450 2D6 inhibitor Non-inhibitor 0.8869 CYP450 2C19 inhibitor Non-inhibitor 0.7655 CYP450 3A4 inhibitor Non-inhibitor 0.9194 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9232 Ames test Non AMES toxic 0.5957 Carcinogenicity Non-carcinogens 0.694 Biodegradation Not ready biodegradable 0.851 Rat acute toxicity 2.3846 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9589 hERG inhibition (predictor II) Non-inhibitor 0.7157
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Taxonomy
- Classification
- Not classified
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Potentiator
- General Function
- Serine-type endopeptidase inhibitor activity
- Specific Function
- Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade. AT-III inhibits thrombin, matriptase-3/TMPRSS7, as well as factors IXa, Xa and XIa. Its inhibitory a...
- Gene Name
- SERPINC1
- Uniprot ID
- P01008
- Uniprot Name
- Antithrombin-III
- Molecular Weight
- 52601.935 Da
References
- Peng K, Wang C, Pang BS, Yang YH: [Effects of thrombolysis and anticoagulation on the functions of vascular endothelial cells and coagulation and fibrinolysis in patients with pulmonary thromboembolism]. Zhonghua Jie He He Hu Xi Za Zhi. 2005 Sep;28(9):596-9. [PubMed:16207425]
- Lee S, Gibson CM: Enoxaparin in acute coronary syndromes. Expert Rev Cardiovasc Ther. 2007 May;5(3):387-99. [PubMed:17489664]
- Bisio A, Vecchietti D, Citterio L, Guerrini M, Raman R, Bertini S, Eisele G, Naggi A, Sasisekharan R, Torri G: Structural features of low-molecular-weight heparins affecting their affinity to antithrombin. Thromb Haemost. 2009 Nov;102(5):865-73. doi: 10.1160/TH09-02-0081. [PubMed:19888521]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Serine-type endopeptidase activity
- Specific Function
- Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.
- Gene Name
- F10
- Uniprot ID
- P00742
- Uniprot Name
- Coagulation factor X
- Molecular Weight
- 54731.255 Da
References
- Graff J, Picard-Willems B, Harder S: Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a. Int J Clin Pharmacol Ther. 2007 Apr;45(4):237-43. [PubMed:17474542]
- Berges A, Laporte S, Epinat M, Zufferey P, Alamartine E, Tranchand B, Decousus H, Mismetti P: Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old. Br J Clin Pharmacol. 2007 Oct;64(4):428-38. Epub 2007 May 17. [PubMed:17509040]
- Sanchez-Pena P, Hulot JS, Urien S, Ankri A, Collet JP, Choussat R, Lechat P, Montalescot G: Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis. Br J Clin Pharmacol. 2005 Oct;60(4):364-73. [PubMed:16187968]
- Dalmora SL, Junior LB, Schmidt CA, Vaccari SF, Oliveira PR, Codevilla CF: Validation of the anti-factor Xa assay for the potency assessment of enoxaparin in pharmaceutical formulations. J AOAC Int. 2004 Nov-Dec;87(6):1305-8. [PubMed:15675440]
- Paige JT, Gouda BP, Gaitor-Stampley V, Scalia PG, Klainer TE, Raum WJ, Martin LF: No correlation between anti-factor Xa levels, low-molecular-weight heparin, and bleeding after gastric bypass. Surg Obes Relat Dis. 2007 Jul-Aug;3(4):469-75. Epub 2007 Jun 12. [PubMed:17567541]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Other
- General Function
- Peroxidase activity
- Specific Function
- Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production o...
- Gene Name
- MPO
- Uniprot ID
- P05164
- Uniprot Name
- Myeloperoxidase
- Molecular Weight
- 83867.71 Da
References
- Rudolph TK, Rudolph V, Witte A, Klinke A, Szoecs K, Lau D, Heitzer T, Meinertz T, Baldus S: Liberation of vessel adherent myeloperoxidase by enoxaparin improves endothelial function. Int J Cardiol. 2010 Apr 1;140(1):42-7. doi: 10.1016/j.ijcard.2008.10.035. Epub 2008 Dec 2. [PubMed:19049846]
Drug created on June 13, 2005 07:24 / Updated on April 17, 2018 01:05